Compare TG Therapeutics Inc (TGTX) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs T Rowe Price Group Inc — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while T Rowe Price Group Inc trades at $113.73 (market cap $24.26B). The key difference: T Rowe Price Group Inc is far larger — about 3.2× TG Therapeutics Inc's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TROW | |
|---|---|---|
Market Cap | $7.64B | $24.26B |
Sector | Health | Financials |
52-Week High | $59.06 | $121.68 |
52-Week Low | $26.94 | $86.19 |
Enterprise Value | $7.84B | $21.46B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
T. Rowe Price (TROW) trades at $111.49, down 2.0% on the day, with a bearish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 11.42, net income margin of 29.26%, and consistent dividend payments of $1.30 per share. Recent Q2 2026 earnings beat expectations with EPS of $2.57 versus $2.51 estimated, driven by higher assets under management and advisory revenue.
The outlook is mixed: strong profitability and a consensus price target of $112.17 offer upside, but bearish technicals and expense pressures pose risks. Investor sentiment is cautious with 63% analyst hold ratings, reflecting concerns over net outflows and market volatility impacting asset management fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
